IMUN CAR-T Technology
Immune Therapeutics Inc. recently acquired the Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and therapeeutic clinical data from Super-T Cell Cancer Company (“STCC”) a newly formed corporation.
Lodonal™ is Immune Therapeutics, Inc.’s approved immune modulator for use in emerging nations. Lodonal™, based on the Low Dose Naltrexone formulation, IRT-103/Lodonal™ currently in use with Immune’s wholly owned subsidiary Cytocom, Inc.
Met-enkephalin, some times referred to as Opioid Growth Factor (OGF) have been studied by a number of scientists but the most published of these are Dr. Ian Zagon and his team from Pennsylvania State Medical Center at Hershey extensively in relationship to growth – especially in cancer and Dr. Nicholas Plotnikoff in conjunction with. Bihari and Dr. Ronald Herberman and Robert Good in the treatment of HIV/AIDS and cancer. Much of this research has been carried out in the USA, Belgium, Croatia and Germany.
Low Dose Naltrexone (US)
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s collaborator Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial.
2431 Aloma Ave #124 Winter Park, FL 3279